Press Room

Paperless Lab Academy 2018

Start
Tuesday, March 20, 2018 - 00:00
End
Wednesday, March 21, 2018 - 00:00
Location: Milan, Italy

HOVIONE PRESENTATION

Analytical Lab 4.0: from Digital Twin to Intelligent Systems

Presenters

Andrea Costigliola, Miguel Ramos Lopes

Abstract

Pharma 4.0, the extension of the fourth industrial revolution to the pharmaceutical realm, promises to deliver a productivity leap across key focus areas: drug discovery, development, manufacturing, marketing and quality control. Quality Control (QC) is of paramount importance in the pharmaceutical industry, with companies having to follow strict guidelines enforced by regulatory agencies. Laboratory management is a complex task which involves resources (personnel and equipment) planning and scheduling, analyses prioritization, results evaluation and documentation. The demand for QC work is dependent on other operational areas, fluctuating qualitatively and quantitatively over time. Effective communication mechanisms, visualization and management tools can enhance the overall laboratory service level.

Hovione will leverage the opportunity presented by the design of a new – state-of-the-art – Analytical Laboratory to embrace novel technologies and set the bar for a new paradigm of analytical excellence, turning Analytical Chemistry into a catalyst of operations and a differentiating business factor. In this spirit, we will detail Hovione’s approach by presenting some of our Intelligent Tools (QC Digital Twin, Resource Planner, Tracking Systems, etc.) and the roadmap towards the Analytical Lab 4.0.

 

If you are attending this event and would like to chat with us, schedule a meeting with us.

Schedule a meeting button | Hovione

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025